Inhibition of DOT1L impaired the viability of AR positive (AR+) PCa cells, including CRPC and enzalutamide-resistant cells, thus DOTL1 is a potential therapeutic target for PCa. The gene discussed is DOT1L; the disease is posterior cortical atrophy.